Anil Wali, Ph.D.
Center to Reduce Cancer Health Disparities
National Cancer Institute
9609 Medical Center Drive, MSC 9746
Sixth Floor, West Tower, 6W248
Bethesda, MD 20852
phone: (240) 276-6183
fax: (240) 276-7862
Anil Wali, Ph.D. is a Program Director in the Diversity Training Branch for the Center to Reduce Cancer Health Disparities. He provides technical and scientific expertise and grants program administration guidance to trainees and early stage investigators.
Dr. Wali joined CRCHD in 2009 from Wayne State University, Detroit Medical Center and NCI designated Comprehensive Cancer Center Barbara Ann Karmanos Cancer Institute where he served as Associate Professor in the Departments of Surgery and Pathology. Dr. Wali also served as Principal Investigator on a Veterans Administration Merit Review award funded project on the Role of Ubiquitin-Proteasome Pathway in Mesothelioma Carcinogenesis. Dr. Wali conducted NCI Clinical trial on asbestos exposed patient populations to determine their risk for developing Lung Cancer and Mesothelioma using high throughput Genomics and Proteomics technologies.
Dr. Wali received his B.S. and M.S. degrees from the University of Kashmir, in Srinagar, India. He earned his Ph.D. at the Postgraduate Institute in Chandigarh, India. Dr. Wali completed postdoctoral training at the Institute for Environmental Medicine at the University of Pennsylvania; at the FELS Institute for Cancer Research at Temple University, Philadelphia, PA; and in the Department of Pathology at Thomas Jefferson University, Philadelphia, PA.
Select Web Links
Select Publications and Presentations
Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-72, 2008.
Anil Wali, Fulvio Lonardo, Deepa Kanakapalli, Zhandong Liu, Ying Wang, Guri Tzivion, Arun K. Rishi, Michele Carbone, John C. Ruckdeschel, Harvey I. Pass. Differential gene expression profile of Stratifin (14.3.3 sigma) in malignant pleural mesothelioma. American Association for Cancer Research, San Diego, CA, April 12-16, 2008.
Zhang L, Wali A, Ramana CV, Rishi AK. Cell growth inhibition by okadaic acid involves gut-enriched kruppel-like factor-mediated enhanced expression of c-myc. Cancer Res 67: 10198-10206, 2007.
Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 58: 220-230, 2007.
Anil Wali, Ying Wang, Deepa Kanakapalli, Zhandong Liu, Sunita Sharma, Fulvio Lonardo, Arun K. Rishi, Adhip P.N. Majumdar, Q. Ping Dou, Michele Carbone, John C. Ruckdeschel and Harvey Pass. Role of Ubiquitin-Proteasome Proteolytic Pathway in Malignant Pleural Mesothelioma. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
Cortese, JF; Gowda, AL; Wali, A; Eliason, JF; Pass, HI; Everson, RB: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 118: 521-2, 2006.
Anil Wali, Fauzia Siddiq, Deepa Kanakapalli, Zhandong Liu, Fulvio Lonardo, Arun K. Rishi, Adhip P.N Majumdar, Michele Carbone, Henry H.Q Heng, Harvey I. Pass. Intelectin overexpression causes chromosomal aberrations in immortalized human mesothelial cells. American Association for Cancer Research, Washington DC, April 1-5, 2006.
Pass, HI; Lott, D.; Lonardo, F; Harbut, M; Liu, Z; Tang, N; Carbone, M; Webb, C; Wali, A: Exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 353: 1564-73, 2005.
Wali A, PJ Morin, CD Hough, F Lonardo M Carbone, T Seya, and HI Pass. Identification of Intelectin in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer, 48; 19-29, 2005.
Pass HI, Z Liu, A Wali, R Bueno, S Land, D Lott, F Siddiq, F Lonardo, M Carbone, and S Draghici. Gene expression profiles predict survival and progression of pleural mesothelioma. Clinical Cancer Research 10:849-859, 2004. (Featured Covers Article).
Select Book Chapters
Genomics and Proteomics in Mesothelioma: A Wali and HI Pass in Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. HI Pass, NJ Vogelzang, and M Carbone, editors Springer-Verlag, New York 2005
Targeting of Apoptosis Signaling Pathways and their Mediators for cancer Therapy: AK Rishi, X Zhang, A. Wali. in Pharmaceutical Perspectives of Cancer Therapeutics. Editors: Ram I. Mahato and Yi Lu, Springer, New York 2009
HI Pass and A Wali. The use of osteopontin measurements in any body fluid for the early detection, diagnosis, and monitoring of asbestos-related neoplasms specifically including mesothelioma and lung cancer. (WSU FILE # 05-735).